Peptide Association
Start Your Consultation
All peptides
MetabolicFDA Approved

Tirzepatide (Mounjaro/Zepbound)

Subcutaneous injection (weekly)
Written by Peptide Association Editorial TeamMedically reviewed by Ian Justl Ellis, MD, CPTLast reviewed Editorial policy

Overview

A first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. Tirzepatide activates both incretin pathways simultaneously, producing superior glycemic control and weight loss compared to selective GLP-1 RAs.

Mechanism of Action

The dual mechanism enhances insulin sensitivity and lipid metabolism beyond what either pathway achieves alone.

Research Summary & Key Findings

SURMOUNT-1 trial showed up to 22.5% body weight reduction at highest dose. SURPASS trials demonstrated superior HbA1c reduction vs. semaglutide. FDA-approved for type 2 diabetes (Mounjaro, 2022) and chronic weight management (Zepbound, 2023).

Clinical Status

FDA Approved

Tirzepatide (Mounjaro/Zepbound) has received FDA approval and is available for clinical use under appropriate medical supervision. Consult a qualified healthcare provider for prescribing information.

Administration Routes

Subcutaneous injection (weekly)

References

Primary literature

Study-level citations for this compound are being verified against the primary sources before publication. The database queries above return the current indexed literature in the meantime.

Related Peptides in Metabolic

Semaglutide (Ozempic/Wegovy)

FDA Approved

A glucagon-like peptide-1 receptor agonist (GLP-1 RA) with 94% amino acid homology to native GLP-1. Semaglutide enhances...

View details

Retatrutide

In Clinical Trials

An investigational triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. The gluc...

View details

AOD-9604

Investigational

A modified 16-amino acid fragment (amino acids 176-191) of the C-terminus of human growth hormone with an added tyrosine...

View details

Liraglutide (Saxenda/Victoza)

FDA Approved

A GLP-1 receptor agonist with 97% homology to native GLP-1, modified with a fatty acid side chain (C-16 palmitoyl) enabl...

View details

Start Your Consultation

Get an AI-proposed Tirzepatide (Mounjaro/Zepbound) protocol reviewed by a physician in our network.

Start Your Consultation

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Tirzepatide (Mounjaro/Zepbound).

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.